生物瓣替换术后华法林和阿司匹林抗凝的疗效比较  

The Anticoagulation Effect of Warfarin vs Aspirin after Bio-prosthetic Heart Valve Replacement

作　　者：夏利民[1] 赵强[1] 徐德民[1] 孙勇新[1] 朱丹[1] 

机构地区：[1]复旦大学附属中山医院心外科,上海200032

出　　处：《中国临床医学》2006年第4期552-553,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:通过对生物瓣替换手术病人抗凝治疗的随访,比较华法林抗凝治疗和抗血小板药物阿司匹林治疗的远期生存率和抗凝并发症发生率。方法:自2000年4月-2005年11月生物瓣替换手术成功出院病人220例,分为2组,其中华法林抗凝治疗组148例(A组),不用华法林治疗组72例(B组),包括使用阿司匹林抗凝病人65例,不抗凝治疗病人7例。术后通过信访和电话随访,门诊随访,了解2组病人的预后及抗凝并发症的发生率。结果:术后随访0．5-5．5年,随访202例,失访18例,随访率91．8％。服用华法林抗凝组(A组),随访到135例,其中死亡4例,均为突然死亡,其中明确脑出血的有3例,随访期间发生消化道出血4例,脑溢血3例,中风5例,皮肤出血10例,血尿4例,发生短暂晕厥9例。服用阿司匹林组或不抗凝组(B组),随访到67例,死亡0例,消化道出血2例,中风2例,血尿1例,发生晕厥1例,皮肤紫癜0例。结论:生物瓣置换术后,不用华法林抗凝治疗,用抗血小板药物阿司匹林治疗并不增加死亡率和抗凝并发症发生率。Objective：To compare the anticoagulation effect of warfarin and anti-platelet drugs after bio-prosthetic heart valve replacement. Methods：After success of prosthetic heart valve replacement, 202 patients were followed up from April 2000 to Nov. 2005. All parients were divided into two groups. Group A （n= 148） was given warfarin while Group B （n= 72） given anti-platelet drug aspirin or without any anticoagulation drug. We followed up the survival and post-operative complications for 0. 5 -5.5 years. Results： There was no differences in anticoagulation effect between two groups but low occurrence of bleeding in Group B with anti-platelet drug. Conclusion： We can use the anti-platelet drugs such as aspirin after bio-prosthetic heart valve replacement safely.

关 键 词：生物瓣 抗凝治疗 

分 类 号：R318.11[医药卫生—生物医学工程]